I am a board certified oncologist and hematologist specializing in the treatment of patients with lymphoma. My research has focused on evaluating novel treatments for Hodgkin lymphoma.
- Clinical Expertise: Hodgkin and non-Hodgkin Lymphoma; Cutaneous T Cell Lymphoma
- Languages Spoken: English
- Education: MD, Albert Einstein College of Medicine
- Residencies: New York-Presbyterian Hospital/Columbia University Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Alison J. Moskowitz
Clinical Trials Co-Investigated by Alison J. Moskowitz
- A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
- A Phase I Study of Ibrutinib in Patients with Recurrent or Persistent T-Cell Lymphoma
- A Phase IB/IIA Study of Carfilzomib, Romidepsin, and Lenalidomide in Patients with Recurrent or Persistent Lymphoma
- A Phase II Study of Pembrolizumab in Patients with Recurrent or Persistent Classical Hodgkin Lymphoma
- A Phase III Study of Brentuximab Vedotin plus CHP versus CHOP Therapy for Patients with Previously Untreated CD30-Positive Peripheral T-Cell Lymphoma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more